Targeted Disease(s):
Pulmonary Fibrosis
Purpose of Study:
The HARBOR Study is evaluating the safety and effectiveness of a potential medicine (HZN-825) that may slow disease progression in participants with idiopathic pulmonary fibrosis (IPF).
Study Dates:
August 25, 2021 - September 30, 2023
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Horizon Therapeutics
Funding Source:
Horizon Therapeutics
ClinicalTrails.gov Identifier:
NCT05032066
